Forte Biosciences, Inc.

FBRX · Nasdaq · SIC 2834: Pharmaceutical Preparations
162
SEC Filings

Business Summary

Overview Forte Biosciences, Inc. and its subsidiaries (www.fortebiorx.com) (Forte, we, our) is a clinical-stage biopharmaceutical company whose current lead product candidate is FB102. FB102 is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Our FB102 program aims to address key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulato...

Next Earnings

Q2 FY2026 — expected 2026-08-19

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionFBRXdiscussed_in_filing Cybersecurity
topic_mentionFBRXdiscussed_in_filing Cybersecurity
topic_mentionFBRXdiscussed_in_filing Healthcare & Bio
topic_mentionFBRXdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-312025-12-310001193125-26-134498EDGAR70K words
2025-03-282024-12-310000950170-25-046749EDGAR—
2024-03-182023-12-310000950170-24-032843EDGAR—
2023-03-312022-12-310000950170-23-011355EDGAR—
2022-03-312021-12-310001564590-22-012987EDGAR—
2021-03-162020-12-310001564590-21-013249EDGAR—
2020-02-272019-12-310001564590-20-007402EDGAR—
2019-02-272018-12-310001564590-19-004933EDGAR—
2018-03-092017-12-310001564590-18-005132EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001193125-25-281808EDGAR53K words
2025-08-142025-06-300000950170-25-108889EDGAR—
2025-05-152025-03-310000950170-25-072569EDGAR—
2024-11-142024-09-300000950170-24-127031EDGAR—
2024-08-142024-06-300000950170-24-096988EDGAR—
2024-05-132024-03-310000950170-24-058669EDGAR—
2023-11-132023-09-300000950170-23-062907EDGAR—
2023-08-142023-06-300000950170-23-042518EDGAR—
2023-05-152023-03-310000950170-23-022184EDGAR—
2022-11-142022-09-300000950170-22-024977EDGAR—
2022-08-152022-06-300000950170-22-017378EDGAR—
2022-05-162022-03-310001564590-22-020257EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-010001193125-26-135767EDGAR2K words
2025-11-140001193125-25-281807EDGAR—
2025-08-140001193125-25-180771EDGAR—
2025-06-250001193125-25-147017EDGAR—
2025-06-230001193125-25-144174EDGAR—
2025-05-300001193125-25-131525EDGAR—
2025-05-150001193125-25-120772EDGAR—
2025-04-180001193125-25-085762EDGAR—
2025-04-040001193125-25-073403EDGAR—
2025-01-240001193125-25-012236EDGAR—

162 total filings indexed. 131 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001419041
TickerFBRX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 65f4c31eb693cce187b82eea7ff4d73b2b24740b57c79f04c7142c700b1485bc
parent: 33fdaf7eb1c6edfcf6d96f611263920c4ffa62750d6de16dd1ca852091aa5baf
content hash: 0396a47ed81dd324f91d56c3747e2d0de662038c81a5a059ff0e04258fd83df6
signed: 2026-04-13T04:44:59.549Z
sources: 21 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf